Ocugen Inc ( (OCGN) ) has released its Q4 earnings. Here is a breakdown of the information Ocugen Inc presented to its investors.
Ocugen, Inc. is a biotechnology company specializing in gene therapies for blindness diseases, aiming to improve health through innovative treatments. The company recently released its fourth quarter and full year 2024 financial results, highlighting significant advancements in its clinical programs. Key achievements include the alignment with the FDA for a Phase 2/3 trial for OCU410ST, positive long-term data for OCU400, and progress in the OCU410 and OCU200 trials. Financially, Ocugen reported a decrease in net loss per share compared to the previous year, with increased cash reserves to support ongoing operations. Looking ahead, Ocugen remains focused on advancing its clinical pipeline and achieving regulatory milestones to address unmet medical needs in retinal diseases.